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Introduction {#cam4666-sec-0001}
============

It is estimated that one‐tenth of all new cancers are diagnosed in patients aged 20 to 39 years [1](#cam4666-bib-0001){ref-type="ref"}. With improvements in early detection and treatment, the majority of these individuals will overcome their disease to become cancer survivors [1](#cam4666-bib-0001){ref-type="ref"}. As this group of young adults transition from being patients to survivors, there is a growing need to address important issues pertaining to their long‐term follow‐up, such as their reproductive and sexual health. Incorporating discussions about these topics early in the course of their cancer is increasingly recognized as an important component of care even though long‐term repercussions of treatments may not always be seen as priorities when patients are first diagnosed with cancer and are still adjusting to the burden of a malignant diagnosis [2](#cam4666-bib-0002){ref-type="ref"}, [3](#cam4666-bib-0003){ref-type="ref"}. It is frequently only after treatment completion that patients face the reality of complications, such as infertility and sexual dysfunction [4](#cam4666-bib-0004){ref-type="ref"}, [5](#cam4666-bib-0005){ref-type="ref"}, [6](#cam4666-bib-0006){ref-type="ref"}, [7](#cam4666-bib-0007){ref-type="ref"}. Many of these patients experience regret and acknowledge in retrospect that they would have taken specific actions to better preserve their reproductive health, if they had been given the opportunity [6](#cam4666-bib-0006){ref-type="ref"}.

Treatments of specific tumors, such as genitourinary and gynecological malignancies can pose direct deleterious effects on fertility since therapies for these particular cancers can often involve chemical or physical removal of the reproductive organs [8](#cam4666-bib-0008){ref-type="ref"}. Many conventional chemotherapy agents can also temporarily or permanently harm reproductive health. In the setting of breast cancer, for instance, up to 80% of patients receiving chemotherapy may experience permanent amenorrhea and face the risk of premature ovarian failure [8](#cam4666-bib-0008){ref-type="ref"}, [9](#cam4666-bib-0009){ref-type="ref"}, [10](#cam4666-bib-0010){ref-type="ref"}. In addition, radiotherapy can have detrimental effects on gonadal function, depending on the dose and the field of irradiation [11](#cam4666-bib-0011){ref-type="ref"}, [12](#cam4666-bib-0012){ref-type="ref"}. One study showed a 20‐fold increased risk of ovarian failure in patients who received irradiation to their abdomen when compared to those who underwent irradiation to other areas [13](#cam4666-bib-0013){ref-type="ref"}. Cancer treatments can also lead to sexual dysfunction [14](#cam4666-bib-0014){ref-type="ref"}. Approximately, 30--100% of breast cancer survivors experience decreased sexual desire and arousal, vaginal dryness, anorgasmia, or dyspareunia [16](#cam4666-bib-0016){ref-type="ref"}, [17](#cam4666-bib-0017){ref-type="ref"}, [18](#cam4666-bib-0018){ref-type="ref"}, [19](#cam4666-bib-0019){ref-type="ref"}, [20](#cam4666-bib-0020){ref-type="ref"}, [21](#cam4666-bib-0021){ref-type="ref"}, [22](#cam4666-bib-0022){ref-type="ref"}, [23](#cam4666-bib-0023){ref-type="ref"}. In another recent study, 54% and 25% of male rectal and colon cancer survivors, respectively, reported erectile dysfunction [15](#cam4666-bib-0015){ref-type="ref"}.

Despite these significant consequences from cancer therapies, a study demonstrated that only 50% of young women with breast cancer recalled having a discussion on reproductive health risks with their healthcare providers prior to embarking on cancer treatments [24](#cam4666-bib-0024){ref-type="ref"}. An even lower proportion of male patients with colorectal cancer reported these discussions [25](#cam4666-bib-0025){ref-type="ref"}. Similarly, the frequency of sexual health discussions between physicians and cancer patients was also found to be low [26](#cam4666-bib-0026){ref-type="ref"}. Of note, prior studies have been small and focused primarily on survey studies which can be subject to recall bias. There has also been a lack of research on factors which predict the occurrence of fertility and sexual health discussions. Thus, the aims of the current population‐based study are to (1) determine the frequency at which reproductive and sexual health discussions occurred in common cancers, and (2) identify clinical factors associated with the occurrence of such conversations. Insights gained from this study can hopefully be used in the future to optimize the follow‐up care of young adult cancer survivors and to ensure that their fertility and sexual function concerns are adequately and promptly addressed.

Methods {#cam4666-sec-0002}
=======

Characteristics of the study setting {#cam4666-sec-0003}
------------------------------------

The British Columbia Cancer Agency is a provincial and population‐based cancer control program that is responsible for funding and providing cancer treatment to approximately 4.5 million residents in the province of British Columbia, Canada. At the time of this study, the agency was comprised of five regional cancer centers that were geographically distributed across different catchment areas of the province in order to ensure equitable access to cancer care irrespective of place of residence. All centers offer a full range of cancer programs including outpatient oncology clinics, chemotherapy suites, radiation facilities, surgical services, inpatient units, palliative and supportive care, and the opportunity to participate in clinical trials for the estimated 15,000--20,000 new patients referred to the British Columbia Cancer Agency annually. This study was conducted upon receiving full approval from the institutional Research Ethics Board.

Description of the patient population {#cam4666-sec-0004}
-------------------------------------

We conducted a retrospective chart review and included consecutive patients diagnosed with selected solid tumors from 2008 to 2010, who were aged 20--39 years at the time, referred to and evaluated at any of the British Columbia Cancer Agency regional cancer centers, and still alive at 2 or more years following their cancer diagnosis. We selected this specific age range as it encompassed a key demographic group in whom fertility may be particularly pertinent, but excluded patients younger than 20 years since these cases are still largely managed by pediatric oncologists in British Columbia. We defined survivors as those surviving beyond 2 years because most active anticancer treatments (except for hormonal therapies) are completed by this time point. This is also consistent with definitions used by prior investigators in existing published literature [27](#cam4666-bib-0027){ref-type="ref"}. We focused on solid tumors that have a growing and young survivorship population, specifically breast, testicular, and gynecological malignancies. Solid tumors that commonly affect older patients were excluded as these cases may have age‐related infertility and thus reproductive health discussions may be less applicable. Hematologic malignancies were further excluded since these are mainly treated at high‐volume transplant centers outside the British Columbia Cancer Agency.

Measurement of outcomes and variables {#cam4666-sec-0005}
-------------------------------------

The main outcome measures included whether a discussion on (1) reproductive health and (2) sexual health occurred at the first oncology consultation with a medical, radiation, or surgical oncologist, and if not, whether either of these topics was discussed within 6 months of the initial visit with any of the oncologists. All physicians at the British Columbia Cancer Agency are provided with standardized guidelines and formats for the dictation of medical notes. Charts were reviewed in full until the first documented conversation pertaining to reproductive and sexual health or until 6 months of the initial consultation, whichever came first. Study outcomes were obtained through evaluation of all electronic medical records by two authors (YW, JYR) who were blinded from each other to ensure consistency in interpretation of clinical information. Discordant interpretations between the two investigators were 3% and disagreements were resolved through consensus by involving the senior investigator (WYC) who conducted a separate review. For the purposes of this study, conversations about reproductive health were considered to have occurred if records described any of the following: current or future family planning, impact of treatment on fertility, or options regarding fertility preservation (e.g., sperm banking or egg retrieval). Likewise, sexual health discussions were deemed to have taken place if records described discussion of any of the following: treatment effects on sexual dysfunction, use of contraceptives, sexual activity during treatment, or interventions to manage symptoms of impotence or decreased libido. For the purposes of this study, fertility preservation was defined as (1) referral or involvement of fertility specialists or clinics to discuss options such as sperm banking in males or egg preservation in females, or (2) opting for fertility sparing treatments. Additional covariates were collected for analyses, such as patient demographics (e.g., gender, age at diagnosis), clinical characteristics (e.g., ECOG \[Eastern Cooperative Oncology Group\] performance status)[28](#cam4666-bib-0028){ref-type="ref"}, and treatment parameters (e.g., modality of therapy, treatment location). We also considered relationship status, number of biological or adopted children, and cancer history in a first degree relative in the analysis because the presence of any one of these factors may increase patients\' awareness of reproductive and sexual health issues and prompt them to proactively engage in conversations about these topics with their physicians.

Statistical analyses {#cam4666-sec-0006}
--------------------

Patient demographics and clinical characteristics were summarized with descriptive statistics. The Chi‐squared and Fisher\'s exact tests were used to assess for variations in features between patient groups. Logistic regression models were constructed to examine for predictors of reproductive and sexual health discussions while adjusting for confounders. Covariates that were clinically significant as well as those found to be significantly associated with outcomes on univariate analyses were considered in a backwards selection procedure to refine the models such that covariates that did not significantly improve model fitness as per the likelihood ratio test were removed one at a time. Because results for discussions at baseline and at 6 months were similar, mainly findings at baseline are presented. All tests were two sided where a *P*‐value of \<0.05 was considered statistically significant. The statistical software program SAS 9.3 (Cary, NC, USA) was used for all statistical analyses.

Results {#cam4666-sec-0007}
=======

Patient characteristics {#cam4666-sec-0008}
-----------------------

We identified a total of 427 eligible patients. At the time of cancer diagnosis, the median age was 35 years (range 20--39), 124 (29%) were men, 375 (88%) had ECOG 0, 336 (79%) were in a relationship, 210 (49%) had children, and 122 (29%) reported a family history of cancer among first degree relatives. In this study cohort, patients were most commonly diagnosed with breast cancer (*N* = 225; 53%) followed by testicular cancer (*N* = 124; 29%), and gynecological malignancies (*N* = 78; 18%). Additional clinical characteristics are summarized in Table [1](#cam4666-tbl-0001){ref-type="table-wrap"}.

###### 

Patient characteristics at time of initial consultation

  Characteristics                                       *N*   \%
  ----------------------------------------------------- ----- -------
  Age                                                         
  \<31                                                  94    22.01
  31--34                                                99    23.19
  35--38                                                167   39.11
  39+                                                   67    15.69
  Sex                                                         
  Female                                                303   70.96
  Male                                                  124   29.04
  ECOG (Eastern Cooperative Oncology Group)                   
  0                                                     375   87.82
  1 or 2                                                52    12.18
  Relationship Status                                         
  Single                                                91    21.31
  Partner                                               336   78.69
  Children at initial consultation                            
  Had children                                          210   49.18
  No children                                           217   50.82
  Family history of cancer                                    
  No                                                    169   39.58
  Yes                                                   258   60.42
  Family history of cancer among 1st degree relatives         
  No                                                    305   71.43
  Yes                                                   122   28.57
  Comorbidities                                               
  No                                                    259   60.66
  Yes                                                   168   39.34
  Tumor Group                                                 
  Breast                                                225   52.69
  Testicular                                            124   29.04
  Gynecological                                         78    18.27
  Treatment Site                                              
  Other                                                 213   49.88
  Teaching hospital                                     214   50.12
  Chemotherapy planned                                        
  No                                                    147   34.43
  Yes                                                   280   65.57
  Radiotherapy planned                                        
  No                                                    222   51.99
  Yes                                                   205   48.01
  Surgery planned                                             
  No                                                    330   77.28
  Yes                                                   97    22.72
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Reproductive health discussions {#cam4666-sec-0009}
-------------------------------

In terms of patient--physician conversations, 249 (58%) had discussions about reproductive health at the initial consultation, with 66% of these held by medical oncologists. By 6 months, an additional 29 (7%) patients had undergone discussions about fertility of which most (93%) were also led by medical oncologists (Table [2](#cam4666-tbl-0002){ref-type="table-wrap"}). On univariate analyses, patients already in relationships and those with a known family history of cancer among first degree relatives were more likely to have had discussions about their fertility at the initial consultation (*P* = 0.03 and *P* = 0.05, respectively). In both univariate and multivariate analyses, there was also a significant association between reproductive health conversations and sexual health conversations in that those who engaged in dialog about one topic were more likely to participate in discussions about the second topic (univariate: *P* = 0.01, multivariate: OR 3.06, 95% CI 1.20--7.87, *P* = 0.02). Tables [3](#cam4666-tbl-0003){ref-type="table-wrap"} and [4](#cam4666-tbl-0004){ref-type="table-wrap"} highlight in detail the clinical factors associated with the occurrence of a reproductive health discussion on univariate and multivariate analyses, respectively.

###### 

Frequency of sexual and reproductive health discussions conducted by medical (MO), radiation (RO), and surgical oncologists (SO)

  Characteristics                                                              Frequency of discussions   \% of Patients with discussions   Distribution of discussions by MO versus. RO/SO
  ---------------------------------------------------------------------------- -------------------------- --------------------------------- ------------------------------------------------------
  Sexual health at initial consultation                                        32/427                     7.49%                             41% versus 59%
  Sexual Health within 6 months after initial consultation                     50/427                     11.71%                            67% versus 33%[a](#cam4666-note-0002){ref-type="fn"}
  Reproductive health discussion at initial consultation                       249/427                    58.31%                            66% versus 34%
  Reproductive health discussions within 6 months after initial consultation   278/427                    65.11%                            93% versus 7%[b](#cam4666-note-0003){ref-type="fn"}

Percentage distribution reflects the additional 18 patients who had a sexual health discussion by 6 months.

Percentage distribution reflects the additional 29 patients who had a reproductive health discussion by 6 months.
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###### 

Univariate analysis of factors associated with fertility and sexual health discussions, and fertility preservation

                                                         Fertility Discussion   Sexual Health Discussion   Fertility Preservation                                                                          
  ------------------------------------------------------ ---------------------- -------------------------- ------------------------ -------- ---------- -------- -------- -------------- -------- -------- --------------
  Age+                                                   \<31                   94                         52                       55.3     0.69       3        3.2      0.02           29       30.9%    **\<0.0001**
  31--34                                                 99                     60                         60.6                     10       10.1       28       28.3%                                     
  35--38                                                 167                    101                        60.5                     9        5.4        23       13.8%                                     
  39+                                                    67                     36                         53.7                     10       14.9       4        6.0%                                      
  Sex                                                    Female                 303                        182                      60.1     0.25       26       8.6      0.18           45       14.9%    **\<0.0001**
  Male                                                   124                    67                         54.0                     6        4.8        39       31.5%                                     
  ECOG+                                                  0                      375                        222                      59.2     0.32       28       7.5      0.95           78       20.8%    0.12
  1 or 2                                                 52                     27                         51.9                     4        7.7        6        11.5%                                     
  Relationship Status                                    Single                 91                         44                       48.4     **0.03**   7        7.7      0.94           24       26.4%    0.07
  Partner                                                336                    205                        61.0                     25       7.4        60       17.9%                                     
  Children at Initial Consultation                       Had children           210                        119                      56.7     0.50       16       7.62     0.92           19       9.05%    **\<0.0001**
  No children                                            217                    130                        59.9                     16       7.37       65       30.0%                                     
  Family history of cancer                               No                     169                        91                       53.9     0.13       12       7.1      0.80           28       16.6%    0.19
  Yes                                                    258                    158                        61.2                     20       7.8        56       21.7%                                     
  Family history of cancer Among 1st degree relatives+   No                     305                        169                      55.4     **0.05**   17       5.6      **0.02**       62       20.3%    0.59
  Yes                                                    122                    80                         65.6                     15       12.3       22       18.0%                                     
  Comorbidities                                          No                     259                        151                      58.3     0.99       17       6.6      0.36           57       22.0%    0.13
  Yes                                                    168                    98                         58.3                     15       8.9        27       16.1                                      
  Tumor Group+                                           Breast                 225                        129                      57.3     0.14       11       4.9      **\<0.0001**   24       10.7     **\<0.0001**
  Testicular                                             124                    67                         54.0                     6        4.8        39       31.5                                      
  Gynecological                                          78                     53                         67.9                     15       19.2       21       26.9                                      
  Treatment Site                                         Other                  213                        126                      59.2     0.73       14       6.6      0.47           32       15.0%    **0.02**
  Teaching hospital                                      214                    123                        57.5                     18       8.4        52       24.3                                      
  Chemotherapy Planned                                   No                     147                        91                       61.9     0.38       12       8.2      0.70           33       22.4     0.30
  Yes                                                    280                    159                        56.8                     20       7.1        51       18.2                                      
  Radiotherapy planned                                   No                     222                        134                      60.4     0.37       12       5.4      0.09           62       27.9     **\<0.0001**
  Yes                                                    205                    115                        56.1                     20       9.8        22       10.7                                      
  Surgery planned                                        No                     330                        187                      56.7     0.20       24       7.3      0.75           58       17.6     **0.04**
  Yes                                                    97                     62                         63.9                     8        8.2        26       26.8                                      
  Sexual health discussions at initial consultation      No                     395                        223                      56.5     **0.01**   **--**   **--**   **--**         **--**   **--**   **--**
  Yes                                                    32                     26                         81.3                     **--**   **--**     **--**   **--**                                    

Bold values represent statistically significant values on univariate analysis.
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###### 

Multivariate analysis of factors associated with fertility and sexual health discussions, and fertility preservation

                                                                        Fertility discussion   Sexual health discussion   Fertility preservation                                                                                                    
  ------------------------------------------------------ -------------- ---------------------- -------------------------- ------------------------ ------------- ------------- ------ ------------ ------- ------------- -------------- ----------- ----
  Age+                                                   \<31           1                      --                         --                       --            1             --     --           --      1             --             --          --
  31--34                                                 1.05           0.57--1.93             0.61                       0.68                     3.72          0.94--14.72   0.25   0.05         0.69    0.31--1.49    0.16           **0.01**    
  35--38                                                 1.06           0.60--1.89             0.50                       2.01                     0.51--7.99    0.48          0.43   0.20--0.91   0.73                                             
  39+                                                    0.74           0.37--1.47             0.24                       5.58                     1.37--22.76   0.02          0.16   0.05--0.55   0.01                                             
  ECOG+                                                  0              1                      --                         --                       --            1             --     --           --      1             --             --          --
  1 or 2                                                 1.27           0.70--2.33             0.43                       --                       1.03          0.33--3.24    0.96   --           1.83    0.65--5.17    0.25           --          
  Relationship status                                    Single         1                      --                         --                       --            --            --     --           --      --            --             --          --
  Partner                                                1.59           0.97--2.60             0.06                       --                       --            --            --     --           --      --            --             --          
  Children at initial consultation                       Had children   --                     --                         --                       --            --            --     --           --      1             --             --          --
  No children                                            --             --                     --                         --                       --            --            --     --           3.13    1.64--5.98    **0.0005**     --          
  Family History of cancer among 1st degree relatives+   No             1                      --                         --                       --            1             --     --           --      --            --             --          --
  Yes                                                    1.37           0.87--2.16             0.17                       --                       1.82          0.84--3.98    0.13   --           --      --            --             --          
  Tumor group+                                           Breast         1                      --                         --                       --            1             --     --           --      1             --             --          --
  testicular                                             0.94           0.58--1.53             0.31                       0.35                     1.38          0.47--4.03    0.32   **0.001**    3.43    1.74--6.78    0.007          **0.002**   
  Gynecological                                          1.44           0.81--2.57             0.15                       5.13                     2.17--12.12   0.001         2.11   0.97--4.59   0.72                                             
  Treatment site                                         Other          --                     --                         --                       --            --            --     --           --      1             --             --          --
  Teaching hospital                                      --             --                     --                         --                       --            --            --     --           1.80    0.97--3.56    0.06           --          
  Sexual health discussion at initial consultation       No             1                      --                         --                       --            --            --     --           --      --            --             --          --
  Yes                                                    3.06           1.20--7.87             0.02                       --                       --            --            --     --           --      --            --             --          
  Fertility discussion at Initial consultation           No             --                     --                         --                       --            --            --     --           --      1             --             --          --
  Yes                                                    --             --                     --                         --                       --            --            --     --           13.06   5.75--29.62   **\<0.0001**   --          

Note that a backwards selection procedure was used to refine the models so that covariates that did not significantly improve model fitness as per the likelihood ratio test were removed one at a time.

ECOG, Eastern Cooperative Oncology Group.

Bold values represent statistically significant values on multivariate analysis.
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Sexual health discussions {#cam4666-sec-0010}
-------------------------

Only 32 (7%) patients had a conversation about sexual health at their initial consultation, with 59% of these initiated by radiation or surgical oncologists. An additional 18 (4%) patients received a sexual health discussion by 6 months of which the majority (67%) were conducted by medical oncologists (Table [2](#cam4666-tbl-0002){ref-type="table-wrap"}).

On univariate analysis, those with a known family history of cancer among first‐degree relatives were more likely to have had sexual health conversations (*P* = 0.02). In addition, gynecological patients engaged in sexual health discussions more frequently than breast or testicular patients (*P* \< 0.0001). In multivariate analysis, individuals affected by gynecological malignancies continued to experience significantly higher odds of having a sexual health discussion when compared to their counterparts (OR 5.13, 95% CI 2.17--12.12, *P* = 0.001). Factors associated with sexual health discussions on univariate and multivariate analyses are summarized in Table [3](#cam4666-tbl-0003){ref-type="table-wrap"} and Table [4](#cam4666-tbl-0004){ref-type="table-wrap"}, respectively.

Taking action toward fertility preservation {#cam4666-sec-0011}
-------------------------------------------

In the entire cohort, 84 (19%) patients took action toward fertility preservation of whom 17 (20%) opted for fertility sparing treatments and 32 (38%) were further referred to reproductive specialists. Of the 17 patients who opted for fertility sparing treatments, 12 cervical cancer patients underwent vaginal trachelectomy instead of standard hysterectomy, four endometrial cancer patients received high‐dose progesterone therapy rather than surgery, and one ovarian cancer patient kept her contralateral ovary in order to preserve future fertility. Tables [3](#cam4666-tbl-0003){ref-type="table-wrap"} and [4](#cam4666-tbl-0004){ref-type="table-wrap"} show clinical factors associated with fertility preservation. On univariate analysis, older individuals (*P* \< 0.0001), females (*P* \< 0.0001), and patients already with children (*P* \< 0.0001) were less likely to take specific actions to protect their fertility. Although patients who were undergoing surgery were more likely to undergo fertility preservation than those in whom surgery was not planned (*P* = 0.04), patients who were receiving radiation were actually less likely to pursue fertility preservation than those not being treated with radiation (*P* \< 0.0001). In addition, patients affected by testicular and gynecological cancers were more inclined to undergo fertility preservation than patients with breast cancer (*P* \< 0.0001), as were those treated at teaching hospitals versus nonteaching hospitals (*P* = 0.02).

On multivariate analysis, similar findings were observed in that patients in the oldest age group were less likely to pursue fertility preservation (OR 0.16, 95% CI 0.05--0.55, *P* = 0.01). Conversely, individuals with testicular and gynecological cancers (OR 3.43, 95% CI 1.74--6.78 and OR 2.11, 95% CI 0.97--4.59, respectively, *P* = 0.002), patients with no children, and those with a prior reproductive health discussion (OR 3.13, 95% CI 1.64--5.98, *P* = 0.0005 and OR 13.06, 95% CI 5.75--29.62, *P* \< 0.0001, respectively) had significantly higher odds of proceeding with actions to preserve their fertility. There was also a persistent trend for patients seen at teaching hospitals to pursue fertility preservation more than those seen at nonteaching centers (OR 1.80, 95% CI 0.97--3.56, *P* = 0.06). Having a reproductive health discussion was strongly correlated with fertility preservation (Tables [3](#cam4666-tbl-0003){ref-type="table-wrap"} and [4](#cam4666-tbl-0004){ref-type="table-wrap"}).

Discussion {#cam4666-sec-0012}
==========

This study represents one of the largest analyses to describe the frequency of fertility and sexual health discussions in young adult cancer survivors of common solid tumors. Contrary to the recommendations from the American Society of Clinical Oncology (ASCO) [8](#cam4666-bib-0008){ref-type="ref"} which highlight the importance of addressing reproductive and sexual health needs, our results indicate that discussions of these issues occur inadequately. This pattern was observed at the first consultation prior to initiation of cancer treatment, and persisted after six months. Specific factors such as relationship status and tumor site were correlated with engaging in these conversations. In turn, conversations about reproductive health were significantly associated with an increased likelihood of pursuing options for fertility preservation.

Prior research suggests that there may be a discrepancy between patients\' and oncologists\' perceptions of fertility discussions. Although surveys of patients indicate that only 34--72% report participating in reproductive health conversations [3](#cam4666-bib-0003){ref-type="ref"}, [6](#cam4666-bib-0006){ref-type="ref"}, [10](#cam4666-bib-0010){ref-type="ref"}, [24](#cam4666-bib-0024){ref-type="ref"}, [29](#cam4666-bib-0029){ref-type="ref"}, [30](#cam4666-bib-0030){ref-type="ref"}, similar surveys of oncologists report that 95--97% of physicians routinely discussed the potential impact of cancer treatment on fertility [31](#cam4666-bib-0031){ref-type="ref"}, [32](#cam4666-bib-0032){ref-type="ref"}. This apparent disconnect may be due in part to the recall bias inherent to surveys [3](#cam4666-bib-0003){ref-type="ref"}, potential barriers in patient--physician communication [33](#cam4666-bib-0033){ref-type="ref"}, or different views between patients and providers about the aspects of fertility and sexual function that actually warrant dialog [34](#cam4666-bib-0034){ref-type="ref"}, [35](#cam4666-bib-0035){ref-type="ref"}. Importantly, our study confirms that the frequency of clinically documented discussions about reproductive and sexual health is more consistent with the patient\'s recall than the physician\'s, underscoring that there are significant unmet needs [8](#cam4666-bib-0008){ref-type="ref"}, [29](#cam4666-bib-0029){ref-type="ref"}, [33](#cam4666-bib-0033){ref-type="ref"}.

Among those who had a reproductive health discussion, one noteworthy finding is that most occurred during the initial consultation before cancer treatment started. To some extent, this is reassuring because early conversations allow an opportunity for patients to fully consider options for fertility preservation [8](#cam4666-bib-0008){ref-type="ref"}. As shown in this as well as other studies [36](#cam4666-bib-0036){ref-type="ref"}, [37](#cam4666-bib-0037){ref-type="ref"}, [38](#cam4666-bib-0038){ref-type="ref"}, a significant proportion of patients who participated in reproductive health discussions subsequently pursued options to preserve their fertility. After adjusting for confounders, having a discussion was the strongest predictor of fertility preservation. This underscores the value of these conversations and the missed opportunity that may occur if adequate dialog fails to take place before cancer treatment is initiated. Many patients who are not given this opportunity experience regret [39](#cam4666-bib-0039){ref-type="ref"}.

Conversations about sexual health were particularly deficient even though research indicates that this is a significant concern among patients [3](#cam4666-bib-0003){ref-type="ref"}. Reasons for the lack of discussion may include poor awareness of treatment options for sexual function [40](#cam4666-bib-0040){ref-type="ref"}, time and resource limitations to address the topic appropriately [35](#cam4666-bib-0035){ref-type="ref"}, and potential concerns regarding the discomfort and negative rapport that may result if such conversations are not conducted sensitively [31](#cam4666-bib-0031){ref-type="ref"}, [41](#cam4666-bib-0041){ref-type="ref"}, [42](#cam4666-bib-0042){ref-type="ref"}. In this study, there was a correlation between reproductive and sexual health conversations in that those who engaged in dialog about one topic were more likely to participate in discussions about the other, suggesting that comfort and openness about these delicate issues can have a significant impact on willingness to discuss them [8](#cam4666-bib-0008){ref-type="ref"}, [43](#cam4666-bib-0043){ref-type="ref"}, and should be a focus of future quality improvement.

We observed a relationship between tumor site and fertility preservation where patients with testicular or gynecological cancers were more inclined to proceed with strategies to protect their fertility. Because management for these tumor sites can frequently involve removal of or modification to the reproductive anatomy, this may serve as strong motivation for patients and physicians to more openly discuss fertility implications. The perceived ease and lower costs of sperm banking when compared to egg retrieval and cryopreservation may further explain why testicular cancer patients were most likely to embark on fertility preservation [44](#cam4666-bib-0044){ref-type="ref"}. With advances in fertility preservation, however, the number of available options is increasing while the costs are decreasing, and thus should encourage discussions across all tumor groups.

Additional factors that were associated with discussions and pursuit of fertility preservation included individuals in a relationship and patients treated at teaching hospitals, respectively. These observations highlight that there could be potential biases in the way patients and physicians approach fertility. While those with a partner or spouse may be viewed conventionally as having more desire or readiness to discuss reproductive health [45](#cam4666-bib-0045){ref-type="ref"}, an increasing number of individuals opt for single parenthood at a later stage in their lives because of specific personal, lifestyle, and professional reasons [46](#cam4666-bib-0046){ref-type="ref"}. Further, fertility preservation remains a highly specialized therapeutic area and a stronger propensity to pursue fertility preservation options at teaching hospitals suggests that access to fertility services may be an ongoing barrier. These disparities indicate a need to develop appropriate models of care delivery that can standardize the way in which fertility is addressed across all demographic and geographic groups.

Interestingly, our results did not reflect any statistically significant sex difference in the likelihood of having reproductive and sexual health discussions. This is in contrast to a survey study by Armuand et al., which reported significantly greater proportion of males having had such discussions when compared to females [47](#cam4666-bib-0047){ref-type="ref"}. A possible explanation for this discrepancy could be the difference in the study cohorts. While our study reviewed patients with breast, testicular, or gynecological malignancies, Armuand et al. also included those with lymphoma and leukemia in the analysis [47](#cam4666-bib-0047){ref-type="ref"}. Moreover, the survey study was conducted in Sweden [47](#cam4666-bib-0047){ref-type="ref"}, which possibly had a different set of factors influencing the likelihood of fertility discussions. In addition, recall bias which is common in surveys was likely present in the study of Armuand et al., since they also uncovered inconsistencies between physician and patient report of fertility discussions [47](#cam4666-bib-0047){ref-type="ref"}.

Our findings should be interpreted in the context of several limitations. First, it is possible that the true frequency of reproductive or sexual health discussions was underestimated since conversations may have occurred without them being documented. However, it is reasonable to expect that any discussions of significant length or detail would appear in the medical records as would any other pertinent topics that were reviewed with the patient by the physician. Clinical documentation of discussions at the time they occurred is more accurate and less variable than physician and patient recall, respectively [48](#cam4666-bib-0048){ref-type="ref"}, [49](#cam4666-bib-0049){ref-type="ref"}. Second, this study was limited to the evaluation of three prevalent tumor types, namely breast, testicular, and gynecological cancers, so our findings may not be generalizable to other malignancies that can occasionally affect young adults, such as lymphoma or melanoma. Likewise, we limited our study cohort to those aged 20--39 years, so our results may not be applicable to older individuals in whom reproductive and sexual health may be equally important. Further, since all patients who opted for fertility sparing treatments were those faced with surgical removal of their reproductive organs, we were not able to provide insights on the impact of chemotherapy and radiation on patient treatment preferences. However, these limitations must also be weighed against the study\'s strengths, which include its relatively large sample size as well as its examination of other young adult malignancies in addition to breast cancer.

In conclusion, the impact of cancer and its treatment on fertility and sexual function was inadequately addressed with patients at the time of their diagnosis, even though such discussions appear to provide patients with increased opportunities to pursue fertility preservation strategies. There were disparities in reproductive and sexual health discussions within specific demographic groups, tumor sites, and treatment locations even though these issues are important for most patients. Better integration of these topics into our routine interactions with patients should be a priority and can mitigate the perceived discomfort surrounding reproductive and sexual health. This is particularly relevant in light of the increasing number of effective treatment options for infertility and sexual dysfunction that are available for the growing number of cancer survivors.
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